[1]张亮,王凤鹿,李小强,等.白藜芦醇通过下调CD44表达抑制胶质瘤U251细胞增殖和侵袭[J].中国临床神经外科杂志,2022,27(08):667-671.[doi:10.13798/j.issn.1009-153X.2022.08.013]
　ZHANG Liang,WANG Feng-lu,LI Xiao-qiang,et al.Resveratrol inhibits the proliferation and invasion of glioma U251 cells through down-regulation of CD44[J].,2022,27(08):667-671.[doi:10.13798/j.issn.1009-153X.2022.08.013]
点击复制

白藜芦醇通过下调CD44表达抑制胶质瘤U251细胞增殖和侵袭()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
27
期数:
2022年08期
页码:
667-671
栏目:
实验研究
出版日期:
2022-08-31

文章信息/Info

Title:
Resveratrol inhibits the proliferation and invasion of glioma U251 cells through down-regulation of CD44
文章编号:
1009-153X(2022)08-0667-05
作者:
张亮; 王凤鹿; 李小强; 王林林; 陈鹏; 蒋小兵; 赵海康
710038 西安，西安医学院第二附属医院神经外科（张亮、王凤鹿、李小强、王林林、陈鹏、蒋小兵、赵海康）
Author(s):
ZHANG Liang;  WANG Feng-lu;  LI Xiao-qiang;  WANG Lin-linm;  CHEN Peng;  JIANG Xiao-bing;  ZHAO Hai-kang
Department of Neurosurgery, Second Affiliated Hospital of Xi'an Medical College, Xi'an 710038, China
关键词:
胶质瘤; 白藜芦醇; U251细胞; 细胞增殖; 细胞侵袭; CD44
Keywords:
Glioma;  Resveratrol;  U251 cell;  Cell Proliferation;  Cell invasion;  CD44
分类号:
R739.41
DOI:
10.13798/j.issn.1009-153X.2022.08.013
文献标志码:
A
摘要:
目的 探讨白藜芦醇对脑胶质瘤细胞增殖和侵袭的影响及可能的分子调控机制。方法 体外培养胶质瘤U251细胞，分别用浓度为0 μmol/L、50 μmol/L、100 μmol/L、150 μmol/L白藜芦醇继续培养48 h，参考Lipofectamine2000TM说明书将pcDNA3.1/CD44（CD44过表达）、pcDNA3.1（过表达对照）等质粒转染胶质瘤U251细胞并培养24 h进行后续实验。利用CCK-8法检测细胞增殖，利用Transwell实验检测细胞侵袭；RT-PCR和免疫印迹法检测细胞CD44、CyclinD1、CDK4、MMP2和MMP9的mRNA和蛋白表达。结果 白藜芦醇明显抑制U251细胞的增殖和侵袭能力（P<0.05），而且呈浓度依赖性（P<0.05）；所以，用150 μmol/L白藜芦醇进行CD44干预实验。白藜芦醇明显抑制U251细胞CD44、CyclinD1、CDK4、MMP2和MMP9的mRNA和蛋白表达（P<0.05），而且呈浓度依赖性（P<0.05）。CD44过表达明显抑制白藜芦醇对胶质瘤U251细胞增殖和侵袭的抑制作用（P<0.05。结论 白藜芦醇抑制胶质瘤细胞增殖和侵袭，其机制与下调CD44的表达有关。
Abstract:
Objective To investigate the effect and possible molecular mechanism of resveratrol on the proliferation and invasion of glioma cells. Methods Glioma U251 cells were cultured in vitro, and were further cultured with resveratrol at concentrations of 0 μmol/L, 50 μmol/L, 100 μmol/L, and 150 μmol/L for 48 h. The plasmids of pcDNA3.1/CD44 (CD44 overexpression) and pcDNA3.1 (overexpression control) were transfected into glioma U251 cells under culture with resveratrol at concentration of 150 μmol/L. Cell proliferation was detected by CCK-8 assay, and cell invasion was detected by Transwell assay. The expressions of mRNA and protein of CD44, CyclinD1, CDK4, MMP2 and MMP9 were detected by RT-CPR and Western blotting, respectively. Results Resveratrol significantly inhibited the proliferation and invasion of U251 cells in a concentration-dependent manner (P<0.05). Resveratrol significantly inhibited the mRNA and protein expressions of CD44, CyclinD1, CDK4, MMP2 and MMP9 in U251 cells in a concentration-dependent manner (P<0.05). Overexpression of CD44 significantly inhibited the inhibitory effect of resveratrol on the proliferation and invasion of glioma U251 cells (P<0.05). Conclusions Resveratrol inhibits the proliferation and invasion of glioma cells, which is related to the down-regulation of CD44 expression.

参考文献/References:

[1]Schwartzbaum JA, Fisher JL, Aldape KD, et al. Epidemiology and molecular pathology of glioma [J]. Nat Clin Pract Neurol, 2006, 2(9): 494-503,516.
[2]Mutter N, Stupp R. Temozolomide: a milestone in neuro-oncology and beyond [J]. Expert Rev Anticancer Ther, 2006, 6(8): 1187-1204.
[3]Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radio-therapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial [J]. Lancet Oncol, 2009, 10(5): 459-466.
[4]Saiko P, Szakmary A, Jaeger W, et al. Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad [J]? Mutat Res, 2008, 658(1-2): 68-94.
[5]Erb U, Megaptche A, Gu X, et al. CD44 standard and CD44v10 isoform expression on leukemia cells distinctly influences niche embedding of hematopoietic stem cells [J]. J Hematol Oncol, 2014, 7: 29.
[6]Han G, Xia J, Gao J, et al. Anti-tumor effects and cellular mechanisms of resveratrol [J]. Drug Discov Ther, 2015, 9 (1): 1-12.
[7]Sato D, Shimizu N, Shimizu Y, et al. Synthesis of glycosides of resveratrol, pterostilbene, and piceatannol, and their anti-oxidant, anti-allergic, and neuroprotective activities [J]. Biosci Biotechnol Biochem, 2014, 78(7): 1123-1128.
[8]Sun Y, Li A, Liu X, et al. A panel of biomarkers for skin squamous cell carcinoma: various functional entities and differential responses to resveratrol [J]. Int J Clin Exp Pathol, 2019, 12 (4): 1363-1377.
[9]Subedi L, Teli MK, Lee JH, et al. A stilbenoid isorhapontigenin as a potential anti-cancer agent against breast cancer through inhibiting sphingosine kinases/tubulin stabilization [J]. Cancers (Basel), 2019, 11(12): 1947.
[10]Khusbu FY, Zhou X, Roy M, et al. Resveratrol induces depletion of TRAF6 and suppresses prostate cancer cell proliferation and migration [J]. Int J Biochem Cell Biol, 2020, 118: 105644-105655.
[11]Yang HC, Wang JY, Bu XY, et al. Resveratrol restores sensitivity of glioma cells to temozolamide through inhibiting the activation of Wnt signaling pathway [J]. J Cell Physiol, 2019, 234(5): 6783-6800.
[12]Jang BI, Li Y, Graham DY, et al. The role of CD44 in the pathogenesis, diagnosis, and therapy of gastric cancer [J]. Gut Liver, 2011, 5(4): 397-405.
[13]Vanje MM, Tanveer S, Ahmed SA, et al. Immunoexperssion of cancer stem cell marker (CD44) in ameloblastoma [J]. J Oral Maxillofac Pathol, 2019, 23(3): 400-406.
[14]Guo JY, Chiu CH, Wang MJ, et al. Proteoglycan serglycin promotes non-small cell lung cancer cell migration through the interaction of its glycosaminoglycans with CD44 [J]. J Biomed Sci, 2020, 27(1): 2.
[15]Hu S, Cao M, He Y, et al. CD44v6 targeted by miR-193b-5p in the coding region modulates the migration and invasion of breast cancer cells [J]. J Cancer, 2020, 11(1): 260-271.
[16]Wang J, Li X, Wu H, et al. EMP1 regulates cell proliferation, migration, and stemness in gliomas through PI3K-AKT signaling and CD44 [J]. J Cell Biochem, 2019, 120 (10): 17142-17150.
[17]Zhang X, Yu J, Zhao C, et al. MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2 [J]. Biomed Pharmacother, 2019, 109: 2192-2202.
[18]Li L, Du Y, Xiang D, et al. Prediction of the anti-glioma therapeutic effects of temozolomide through in vivo molecular imaging of MMP expression [J]. Biomed Opt Express, 2018, 9(7): 3193-3207.
[19]Dai C, Zhang B, Liu X, et al. Pyrimethamine sensitizes pituitary adenomas cells to temozolomide through cathepsin B-dependent and caspase-dependent apoptotic pathways [J]. Int J Cancer, 2013, 133(8): 1982-1993.
[20]Sharma M, Mittapelly N, Banala VT, et al. Amalgamated microneedle array bearing ribociclib-loaded transfersomes eradicates breast cancer via CD44 targeting [J]. Biomacro-molecules, 2022, 23(3): 661-675.
[21]Lee YM, Kim JM, Lee HJ, et al. Immunohistochemical expression of CD44, matrix metalloproteinase2 and matrix metalloproteinase 9 in renal cell carcinomas [J]. Urol Oncol, 2019, 37(10): 742-748.

相似文献/References:

[1]常英男　王　策　赵天书.SOX2基因在胶质瘤中的表达及生物学作用[J].中国临床神经外科杂志,2016,(05):270.[doi:10.13798/j.issn.1009-153X.2016.05.005]
　CHANG Ying-nan,WANG Ce,ZHAO Tian-shu..Expression of SOX2 gene and its biological role in human gliomas[J].,2016,(08):270.[doi:10.13798/j.issn.1009-153X.2016.05.005]
[2]赛　克　陈忠平.胶质瘤的疗效评价[J].中国临床神经外科杂志,2016,(06):321.[doi:10.13798/j.issn.1009-153X.2016.06.001]
[3]许　耿　路俊锋　杨　忠　施建斌　吴秋月　王　烨　庄冬晓　吴劲松.神经电生理监测技术在功能区胶质瘤术中的应用[J].中国临床神经外科杂志,2016,(06):323.[doi:10.13798/j.issn.1009-153X.2016.06.002]
　XU Geng,LU Jun-feng,YANG Zhong,et al.Application of intraoperative neuroelectrophysiologic monitoring to gliomas resection in eloquent function brain regions[J].,2016,(08):323.[doi:10.13798/j.issn.1009-153X.2016.06.002]
[4]李剑峰　陈银生　赛　克　张湘衡　柯　超　杨群英　牟永告　许海雄　陈忠平.173例胶质瘤预后的影响因素分析[J].中国临床神经外科杂志,2016,(06):327.[doi:10.13798/j.issn.1009-153X.2016.06.003]
　LI Jian-feng,CHEN Yin-sheng,SAI Ke,et al.Prognostic factors for gliomas: analysis of 173 cases[J].,2016,(08):327.[doi:10.13798/j.issn.1009-153X.2016.06.003]
[5]云德波　杨宇焦　张　逵　范润金　张　渊　杜贻庆.瘤周谷氨酸、天门冬氨酸水平与胶质瘤继发性 癫痫的相关性[J].中国临床神经外科杂志,2016,(06):331.[doi:10.13798/j.issn.1009-153X.2016.06.004]
　YUN De-bo,YANG Yu-Jiao,ZHANG Kui,et al.Relationship of levels of glutamate and aspartate in peritumorous tissues with seizures in patients with gliomas[J].,2016,(08):331.[doi:10.13798/j.issn.1009-153X.2016.06.004]
[6]黄书岚　成于思　王　辉　汪超甲.FAK siRNA重组质粒的构建及其对胶质瘤U251细胞 增殖及侵袭能力的抑制作用[J].中国临床神经外科杂志,2016,(06):336.[doi:10.13798/j.issn.1009-153X.2016.06.006]
　HUANG Shu-lan,CHENG Yu-si,WANG Hui,et al.Construction of siRNA recombinant plasmid targeting focal adhesion kinase gene and its effect on the proliferation and invasiveness of human glioma U251cells[J].,2016,(08):336.[doi:10.13798/j.issn.1009-153X.2016.06.006]
[7]林　雨　张　恺　李　帅　杨学军.磁共振数字化手术单元在指导胶质瘤治疗中的作用[J].中国临床神经外科杂志,2016,(06):345.[doi:10.13798/j.issn.1009-153X.2016.06.009]
[8]雷军荣　涂献坤　张华斌　张　晶　秦　军　罗　杰　石松生　杨卫忠.白藜芦醇通过激活PI3K/Akt信号通路减轻大鼠脑缺血再灌注损伤[J].中国临床神经外科杂志,2016,(07):425.[doi:10.13798/j.issn.1009-153X.2016.07.012]
　LEI Jun-rong,TU Xian-kun,ZHANG Hua-bin,et al.Resveratrol reduces cerebral ischemia-reperfusion injury through the activation of PI3K/Akt signaling pathway in rats[J].,2016,(08):425.[doi:10.13798/j.issn.1009-153X.2016.07.012]
[9]戴黎明　徐成仕　王泽芬　曹长军　李志强.VEGF单抗对低氧环境下C6胶质瘤细胞侵袭性的影响[J].中国临床神经外科杂志,2016,(04):219.[doi:10.13798/j.issn.1009-153X.2016.04.009]
　DAI Li-ming,XU Cheng-shi,WANG Ze-fen,et al.Effect of nonoclonal antibody of VEGF on C6 glioma cells invasiveness under hypoxia and the role of FAK/Pyk2[J].,2016,(08):219.[doi:10.13798/j.issn.1009-153X.2016.04.009]
[10]彭泽生　田道锋　张申起　陈谦学.miR-370-3p对胶质母细胞瘤U87-MG细胞株增殖能力的影响[J].中国临床神经外科杂志,2016,(04):223.[doi:10.13798/j.issn.1009-153X.2016.04.010]
　PENG Ze-sheng,TIAN Dao-feng,ZHANG Shen-qi,et al.Effects of MircoRNA-370-3p on proliferation of glioma cell line U87-MG and its potential mechanism[J].,2016,(08):223.[doi:10.13798/j.issn.1009-153X.2016.04.010]
[11]胡　森　张　慧　步星耀　冯淼淼　王帮庆　王君毅　杨　斌　杨华超.白藜芦醇对裸鼠胶质瘤模型肿瘤生长的抑制作用[J].中国临床神经外科杂志,2019,(09):543.[doi:10.13798/j.issn.1009-153X.2019.09.010]
　HU Sen,ZHANG Hui,BU Xing-yao,et al.Resveratrol inhibits tumor growth in nude mice model of glioma[J].,2019,(08):543.[doi:10.13798/j.issn.1009-153X.2019.09.010]

备注/Memo

备注/Memo:
（2022-02-22收稿，2022-06-23修回）
通讯作者：赵海康，E-mail：zby0910@163.com
更新日期/Last Update: 2022-09-30